Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
After finishing at $86.85 in the prior trading day, Edwards Lifesciences Corp (NYSE: EW) closed at $86.94, up 0.10%. In other words, the price has increased by $0.10 from its previous closing price. On the day, 1.6 million shares were traded. EW stock price reached its highest trading level at $87.35 during the session, while it also had its lowest trading level at $86.725.
Ratios:
Our goal is to gain a better understanding of EW by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 62.73. For the most recent quarter (mrq), Quick Ratio is recorded 3.29 and its Current Ratio is at 4.00. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
On November 03, 2025, Raymond James Upgraded its rating to Outperform which previously was Mkt Perform but kept the price unchanged to $96.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 12 ’25 when BOBO DONALD E JR sold 11,386 shares for $83.76 per share. The transaction valued at 953,748 led to the insider holds 38,970 shares of the business.
Lippis Daniel J. sold 1,019 shares of EW for $85,625 on Dec 12 ’25. The CVP, JAPAC now owns 22,002 shares after completing the transaction at $84.03 per share. On Dec 12 ’25, another insider, STONE HEISZ LESLIE, who serves as the Director of the company, sold 2,615 shares for $83.41 each. As a result, the insider received 218,120 and left with 30,948 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EW now has a Market Capitalization of 51042480128 and an Enterprise Value of 47370780672. As of this moment, Edwards’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.01, and their Forward P/E ratio for the next fiscal year is 30.14. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.05. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.57 while its Price-to-Book (P/B) ratio in mrq is 4.95. Its current Enterprise Value per Revenue stands at 8.051 whereas that against EBITDA is 26.488.
Stock Price History:
The Beta on a monthly basis for EW is 0.95, which has changed by 0.17317307 over the last 52 weeks, in comparison to a change of 0.17823458 over the same period for the S&P500. Over the past 52 weeks, EW has reached a high of $87.89, while it has fallen to a 52-week low of $65.94. The 50-Day Moving Average of the stock is 3.98%, while the 200-Day Moving Average is calculated to be 11.78%.
Shares Statistics:
The stock has traded on average 4.12M shares per day over the past 3-months and 3277020 shares per day over the last 10 days, according to various share statistics. A total of 580.70M shares are outstanding, with a floating share count of 572.37M. Insiders hold about 1.37% of the company’s shares, while institutions hold 87.76% stake in the company. Shares short for EW as of 1765756800 were 5640466 with a Short Ratio of 1.37, compared to 1763078400 on 9771913. Therefore, it implies a Short% of Shares Outstanding of 5640466 and a Short% of Float of 1.11.
Earnings Estimates
The stock of Edwards Lifesciences Corp (EW) is currently in the spotlight, with 27.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $0.68, with high estimates of $0.72 and low estimates of $0.64.
Analysts are recommending an EPS of between $2.63 and $2.41 for the fiscal current year, implying an average EPS of $2.58. EPS for the following year is $2.87, with 32.0 analysts recommending between $3.12 and $2.65.
Revenue Estimates
27 analysts predict $1.54B in revenue for. The current quarter. It ranges from a high estimate of $1.6B to a low estimate of $1.5B. As of. The current estimate, Edwards Lifesciences Corp’s year-ago sales were $1.39BFor the next quarter, 27 analysts are estimating revenue of $1.57B. There is a high estimate of $1.62B for the next quarter, whereas the lowest estimate is $1.54B.
A total of 32 analysts have provided revenue estimates for EW’s current fiscal year. The highest revenue estimate was $6.1B, while the lowest revenue estimate was $5.89B, resulting in an average revenue estimate of $6.03B. In the same quarter a year ago, actual revenue was $5.44BBased on 32 analysts’ estimates, the company’s revenue will be $6.61B in the next fiscal year. The high estimate is $6.77B and the low estimate is $6.39B.
